IP Library Granted Patent US 10,117,918
Granted Patent B2
US 10,117,918 · App. 15/392,677 · Granted Nov 6, 2018

Antigen-specific T cell receptors and T cell epitopes

Inventors: Ugur Sahin (Mainz, DE); Ozlem Tureci (Mainz, DE); Petra Simon (Mainz, DE); Tana Omokoko (Mainz, DE)
Assignees: BioNTech Cell & Gene Therapies GmbH; Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige Gmbh
A61K39/0011C07K14/7051C12N5/0636C12N9/16C12Y301/03048G01N33/5017A61K2039/57C12N2510/00G01N2333/916
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,918
App. No.
15/392,677
Granted
Nov 6, 2018
Kind
B2
Abstract

The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.

Claims (19)

1. A nucleic acid encoding a T cell receptor selected from the group consisting of:

(I) a T cell receptor comprising:

(i) a T cell receptor α-chain comprising all three CDR sequences of T cell receptor α-chain of SEQ ID NO: 46, and

(ii) a T cell receptor β-chain comprising all three of the CDR sequences of T cell receptor β-chain of SEQ ID NO: 47; and

(II) a T cell receptor comprising:

(i) a T cell receptor α-chain comprising the T cell receptor α-chain sequence of SEQ ID NO: 46, and

(ii) a T cell receptor β-chain comprising the T cell receptor β-chain sequence of SEQ ID NO: 47.

2. An antigen-specific lymphoid cell produced by transferring into a lymphoid cell (i) a nucleic acid encoding a T cell receptor α-chain comprising the T cell receptor α-chain sequence of SEQ ID NO: 46 and a nucleic acid encoding a T cell receptor β-chain comprising the T cell receptor β-chain sequence of SEQ ID NO: 47 or (ii) a nucleic acid encoding a T cell receptor comprising the T cell receptor α-chain sequence of SEQ ID NO: 46 and the T cell receptor β-chain sequence of SEQ ID NO: 47.

3. A pharmaceutical composition comprising the antigen-specific lymphoid cell of claim 2 .

4. An antigen-specific lymphoid cell produced by transferring into a lymphoid cell (i) a nucleic acid encoding a T cell receptor α-chain comprising all three of the CDR sequences of the T cell receptor α-chain sequence of SEQ ID NO: 46 and a nucleic acid encoding a T cell receptor β-chain comprising all three of the CDR sequences of the T cell receptor β-chain sequence of SEQ ID NO: 47 or (ii) a nucleic acid encoding a T cell receptor comprising all three of the CDR sequences of the T cell receptor α-chain sequence of SEQ ID NO: 46 and all three of the CDR sequences the T cell receptor β-chain sequence of SEQ ID NO: 47.

5. A pharmaceutical composition comprising the antigen-specific lymphoid cell of claim 4 .

6. The antigen-specific lymphoid cell of claim 2 , wherein the nucleic acid is RNA.

7. The antigen-specific lymphoid cell of claim 6 , wherein the RNA is in vitro transcribed RNA (IVT RNA).

8. The antigen-specific lymphoid cell of claim 2 , wherein the lymphoid cell is selected from the group consisting of a lymphocyte, lymphoblast and plasma cell.

9. The antigen-specific lymphoid cell of claim 2 , wherein the lymphoid cell is a T cell lacking endogenous expression of a T cell receptor.

10. The antigen-specific lymphoid cell of claim 4 , wherein the nucleic acid is RNA.

11. The antigen-specific lymphoid cell of claim 10 , wherein the RNA is in vitro transcribed RNA (IVT RNA).

12. The antigen-specific lymphoid cell of claim 4 , wherein the lymphoid cell is selected from the group consisting of a lymphocyte, lymphoblast and plasma cell.

13. The antigen-specific lymphoid cell of claim 4 , wherein the lymphoid cell is a T cell lacking endogenous expression of a T cell receptor.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S ADDRESS PREVIOUSLY RECORDED ON REEL 040803 FRAME 0478. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 10, 2017
From: SAHIN, UGUR; TURECI, OZLEM; SIMON, PETRA; OMOKOKO, TANA
To: BIONTECH AG; UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG - UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 041314/0330 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 040803 FRAME 0181. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 10, 2017
From: BIONTECH AG
To: BIONTECH CELL & GENE THERAPIES GMBH
Reel/Frame 041314/0386 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED ON REEL 040803 FRAME 0114. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 10, 2017
From: UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 041314/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 040803/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: BIONTECH AG
To: BIONTECH CELL & GENE THERAPIES GMBH
Reel/Frame 040803/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2016
From: SAHIN, UGUR; TURECI, OZLEM; SIMON, PETRA; OMOKOKO, TANA
To: BIONTECH AG; UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 040803/0478 →
Priority Claims (2)
EP 10009990 · Sep 20, 2010 · regional
EP 11000045 · Jan 5, 2011 · regional
Continuity (2)
Division 13823079
Related Publication 20170112911A1 · Apr 27, 2017
Cited By (3)
US 12,391,742 US 12,589,151 US 12,673,981